Medium materiality5/10
Roth Capital initiates Atrium Therapeutics at Buy with $15 target
Why it may matterVerify against the original reporting
Bullish analyst view, tempered by the fact that this is a single analyst opinion.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Roth Capital initiated coverage of RNA with a Buy rating and a $15 target versus the posted price of $8, implying substantial analyst-estimated upside.
- Roth Capital initiated RNA at Buy.
- Target: $15; posted price: $8.
Key facts
- 01
Target: $15
- 02
Posted price: $8
- 03
Analyst firm: Roth Capital
- 04
Analyst: Boobalan Pachaiyappan
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.